Long‐term outcomes among 2‐year survivors of autologous hematopoietic cell transplantation for Hodgkin and diffuse large b‐cell lymphoma
Abstract
Autologous hematopoietic cell transplantation (auto‐HCT) is a standard therapy for relapsed classic Hodgkin lymphoma (cHL) and diffuse large B‐cell lymphoma (DLBCL); however, long‐term outcomes are not well described.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Nov 10, 2017
- Source ID
- 10.1002/cncr.31114
Entities
People
- Adriana K. Malone
- Amelia Langston
- Amer Beitinjaneh
- Andrew Daly
- Anita D'Souza
- Anne B. Warwick
- Baldeep Wirk
- Bipin N Savani
- Brian T. Hill
- Bronwen E Shaw
- David Buchbinder
- David I. Marks
- Heather R. Millard
- Henry Fung
- Hillard M Lazarus
- Jana Reynolds
- Jean A. Yared
- Keith Stockerl‐goldstein
- Kimberly A. Kasow
- Mary E. D. Flowers
- Matthew J Ehrhardt
- Mehdi Hamadani
- Minoo Battiwalla
- Navneet S Majhail
- Prakash Satwani
- Regina M. Myers
- Richard F. Olsson
- Robert J. Hayashi
- Samantha Jaglowski
- Soyoung Kim
- Steven P. Margossian
- William A. Wood
- Yoshihiro Inamoto
- Zachariah DeFilipp
Organizations
- Baylor University
- Boston Children's Hospital
- Case Western Reserve University
- Children's Hospital of Orange County
- Children's Hospital of Philadelphia
- Cleveland Clinic
- Columbia University
- Emory University
- Fox Chase Cancer Center
- Fred Hutchinson Cancer Center
- Health Resources and Services Administration
- Icahn School of Medicine at Mount Sinai
- Karolinska Institutet
- Medical College of Wisconsin
- National Cancer Center
- National Cancer Institute
- National Heart, Lung, and Blood Institute
- Office of Naval Research
- Ohio State University
- Seattle Cancer Care Alliance
- St. Jude Children's Research Hospital
- University of Maryland
- University of Miami
- University of North Carolina at Chapel Hill
- Uppsala University
- Vanderbilt University
- Washington University in St. Louis